I would like to think I have half a brain, so why would any big pharma not want to keep TBG if it was a valuable technology? Most are diverse enough to absorb into their portfolio, or buy to keep it off the market as a competitive threat. I wish KB luck in negotiating that deal if he can.

All still really rests on getting the EUA on any version of the test. The distribution deals are certainly helpful, but we really don't see the uplift until orders hit the balance sheet, or someone PRs an official financial agreement with volume commitments.

Looking forward to some finality with the SEC in the next few weeks and hopefully agreement with a clinical partner.

Best of luck to all.